<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983628</url>
  </required_header>
  <id_info>
    <org_study_id>TR_9/21</org_study_id>
    <nct_id>NCT04983628</nct_id>
  </id_info>
  <brief_title>Molecular Profiling in Prostate Cancer</brief_title>
  <acronym>ProProstate</acronym>
  <official_title>Prognostic and Predictive Value of Tumor Molecular Alterations in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic&#xD;
      mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes,&#xD;
      including also a few additional clinically relevant genes, in patients with metastatic,&#xD;
      locally advanced or high-grade prostate cancer. In addition, we will investigate the&#xD;
      prognostic role of these mutations as well as their association with various&#xD;
      clinicopathological parameters. This will be the first study investigating the prevalence of&#xD;
      germline and somatic pathogenic mutations in Greek patients with prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include formalin-fixed paraffin-embedded tumor tissue (FFPE) from 250&#xD;
      patients with metastatic, recurrent, locally advanced or &quot;intermediate or high risk&quot; (Gleason&#xD;
      &gt;7), operable prostate cancer. FFPE tumor blocks alongside peripheral blood will be retrieved&#xD;
      for all patients from Pathology Laboratories. Available FFPE blocks will be subjected to&#xD;
      histological review by an experienced pathologist to evaluate H&amp;E sections for confirmation&#xD;
      of diagnosis, histologic type, grade and tumor cell content (TCC%), as well as mark tumor&#xD;
      dense areas for manual macro-dissection, prior to DNA extraction, in order to enrich samples&#xD;
      for tumor DNA. Clinicopathologic characteristics of patients with prostate cancer will be&#xD;
      retrieved from their respective medical records. Diagnosis will be confirmed through&#xD;
      pathology reports, which will also provide information about Gleason Score and histological&#xD;
      subtype.&#xD;
&#xD;
      In all instances, the collection of patient information will be in compliance with the&#xD;
      regulations of the Bioethics committees of participating Hospitals. The study will be&#xD;
      conducted in accordance with the principles of the Helsinki Declaration of Human Rights.&#xD;
&#xD;
      Following manual macro-dissection, FFPE tumor tissue material will be processed for DNA&#xD;
      extraction, according to standard procedures with the QIAamp DNA Mini Kit (Qiagen GmbH,&#xD;
      Hilden, Germany).&#xD;
&#xD;
      Sequencing will be performed at the Laboratory of Molecular Oncology, using an Ion Torrent&#xD;
      Proton Sequencer (Life Technologies/Ion Torrent). For the purpose of targeted NGS genotyping&#xD;
      of tumor and available matched germline DNA samples, we designed a custom Ampliseq panel to&#xD;
      target coding relevant regions of genes involved in homologous recombination (HR), along with&#xD;
      several others.&#xD;
&#xD;
      Data retrieval and base calling will be performed on the Torrent Server (v5.8.0.8).&#xD;
      Consequently, we will then employ appropriate Ion Reporter Workflows (version 5.10) to&#xD;
      automatically annotate single nucleotide variants (SNVs), multiple nucleotide variants&#xD;
      (MNVs), small insertions / deletions (INDELs) and copy number variations (CNVs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of germline and somatic mutations in cancer predisposing genes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with either germline or somatic mutations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from diagnosis to the date of death, through the completion of the study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <condition>Germline BRCA1 Gene Mutation</condition>
  <condition>Germline BRCA2 Gene Mutation</condition>
  <condition>Mutation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor molecular profiling</intervention_name>
    <description>targeted DNA NGS</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed paraffin-embedded tissue samples and germline DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic, recurrent, locally advanced or &quot;intermediate or high risk&quot;&#xD;
        (Gleason &gt;7), operable prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  metastatic prostate cancer&#xD;
&#xD;
          -  recurrent prostate cancer&#xD;
&#xD;
          -  locally advanced prostate cancer&#xD;
&#xD;
          -  &quot;intermediate or high risk&quot; (Gleason &gt;7), operable prostate cancer&#xD;
&#xD;
          -  available FFPE tumor tissue&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  absence of tumor tissue available for analysis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Fountzila Eleni, MD, PhD</last_name>
    <phone>00302310850906</phone>
    <email>elenafou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Moschoni</last_name>
    <phone>00302106912520</phone>
    <email>m_moschoni@hecog.ondsl.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hellenic Cooperative Oncology Group</name>
      <address>
        <city>Athens</city>
        <zip>11524</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fountzila Eleni, MD</last_name>
      <phone>00302310850906</phone>
      <email>elenafou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Predictive biomarker</keyword>
  <keyword>Prognostic biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

